Value of Screening and Treatment of SAHS in the Management of AF Ablation Candidates
NCT04606693
Summary
The present prospective cohort study (not randomized) analyses the value of screening and treatment of SAHS in the management of patients with AF refractory to antiarrhythmics drugs, potentially candidates for ablation. Patients at low risk of suffering from SAHS will follow conventional management of their AF, according to the usual criteria of the Arrhythmia Unit. Patients with high or intermediate risk of SAHS, will undergo respiratory polygraphy. If the result is positive, they will be treated as standard for this syndrome and their heart rate will be monitored for 3 months. After this, the patient's arrhythmic load will be reevaluated differentiating patients into two groups, those that must be ablated from those that have improved their condition and the clinical criteria is no longer ablation but follow-up.
Eligibility
Inclusion Criteria: * Patients with paroxysmal or persistent atrial fibrillation * Recurrent atrial fibrillation despite treatment with at least one class I or III antiarrhythmic * No previous diagnosis of apnea-hypopnea syndrome Exclusion Criteria: * Patients \<18 years * Pregnant women * Doubts about the patient's ability to perform a home respiratory polygraphy * Doubts about the patient's ability to acquire rhythm records with the Kardia system (smartphone required) * Unavailability for follow-up at our center for at least 1 year.
Conditions5
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT04606693